Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults
Efficacy of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 Against TB Disease, in Adults Living in a TB Endemic Region
Sponsor: Aeras
A PHASE2 clinical study on Tuberculosis and Tuberculosis Vaccines, this trial is completed. The trial is conducted by Aeras and has accumulated 11 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
Phase: PHASE2_PHASE3 → PHASE2
-
Jun 2019 — Jan 2020 [monthly]
Completed PHASE2_PHASE3
▶ Show 6 earlier versions
-
Mar 2019 — Jun 2019 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed · Phase: PHASE2 → PHASE2_PHASE3
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aeras
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .